These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 25627091)

  • 1. Penetration of bevacizumab and ranibizumab through retinal pigment epithelial layer in vitro.
    Terasaki H; Sakamoto T; Shirasawa M; Yoshihara N; Otsuka H; Sonoda S; Hisatomi T; Ishibashi T
    Retina; 2015 May; 35(5):1007-15. PubMed ID: 25627091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PERMEABILITY AND ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR EFFECTS OF BEVACIZUMAB, RANIBIZUMAB, AND AFLIBERCEPT IN POLARIZED RETINAL PIGMENT EPITHELIAL LAYER IN VITRO.
    Yoshihara N; Terasaki H; Shirasawa M; Kawano H; Sonoda S; Yamaguchi M; Hashiguchi T; Hisatomi T; Ishibashi T; Sakamoto T
    Retina; 2017 Jan; 37(1):179-190. PubMed ID: 28005721
    [TBL] [Abstract][Full Text] [Related]  

  • 3. VEGF antagonists decrease barrier function of retinal pigment epithelium in vitro: possible participation of intracellular glutathione.
    Miura Y; Klettner A; Roider J
    Invest Ophthalmol Vis Sci; 2010 Sep; 51(9):4848-55. PubMed ID: 20435596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term treatment with anti-VEGF does not induce cell aging in primary retinal pigment epithelium.
    Schottler J; Randoll N; Lucius R; Caliebe A; Roider J; Klettner A
    Exp Eye Res; 2018 Jun; 171():1-11. PubMed ID: 29522724
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of Ranibizumab, Bevacizumab, and Aflibercept on Senescent Retinal Pigment Epithelial Cells.
    Chae JB; Rho CR; Shin JA; Lyu J; Kang S
    Korean J Ophthalmol; 2018 Aug; 32(4):328-338. PubMed ID: 30091312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Minimal effects of VEGF and anti-VEGF drugs on the permeability or selectivity of RPE tight junctions.
    Peng S; Adelman RA; Rizzolo LJ
    Invest Ophthalmol Vis Sci; 2010 Jun; 51(6):3216-25. PubMed ID: 20042644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TNF-α disrupts morphologic and functional barrier properties of polarized retinal pigment epithelium.
    Shirasawa M; Sonoda S; Terasaki H; Arimura N; Otsuka H; Yamashita T; Uchino E; Hisatomi T; Ishibashi T; Sakamoto T
    Exp Eye Res; 2013 May; 110():59-69. PubMed ID: 23454586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Actions of bevacizumab and ranibizumab on microvascular retinal endothelial cells: similarities and differences.
    Deissler HL; Deissler H; Lang GE
    Br J Ophthalmol; 2012 Jul; 96(7):1023-8. PubMed ID: 22539748
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Different properties of VEGF-antagonists: Bevacizumab but not Ranibizumab accumulates in RPE cells.
    Klettner AK; Kruse ML; Meyer T; Wesch D; Kabelitz D; Roider J
    Graefes Arch Clin Exp Ophthalmol; 2009 Dec; 247(12):1601-8. PubMed ID: 19597740
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of differential toxicity of varying doses of bevacizumab on retinal ganglion cells, retinal pigment epithelial cells, and vascular endothelial growth factor-enriched choroidal endothelial cells.
    Brar VS; Sharma RK; Murthy RK; Chalam KV
    J Ocul Pharmacol Ther; 2009 Dec; 25(6):507-11. PubMed ID: 20028259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bevacizumab modulates epithelial-to-mesenchymal transition in the retinal pigment epithelial cells via connective tissue growth factor up-regulation.
    Chen CL; Liang CM; Chen YH; Tai MC; Lu DW; Chen JT
    Acta Ophthalmol; 2012 Aug; 90(5):e389-98. PubMed ID: 22712616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of bevacizumab, ranibizumab, and pegaptanib in vitro: efficiency and possible additional pathways.
    Klettner A; Roider J
    Invest Ophthalmol Vis Sci; 2008 Oct; 49(10):4523-7. PubMed ID: 18441313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intracellular pathways following uptake of bevacizumab in RPE cells.
    Aboul Naga SH; Dithmer M; Chitadze G; Kabelitz D; Lucius R; Roider J; Klettner A
    Exp Eye Res; 2015 Feb; 131():29-41. PubMed ID: 25533679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ranibizumab and Bevacizumab but Not Aflibercept Inhibit Proliferation of Primary Human Retinal Pigment Epithelium in vitro.
    Parisi L; Fuhrer R; Zinkernagel M; Enzmann V
    Ophthalmologica; 2019; 241(3):137-142. PubMed ID: 30001546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative antiproliferative and cytotoxic profile of bevacizumab (Avastin), pegaptanib (Macugen) and ranibizumab (Lucentis) on different ocular cells.
    Spitzer MS; Yoeruek E; Sierra A; Wallenfels-Thilo B; Schraermeyer U; Spitzer B; Bartz-Schmidt KU; Szurman P
    Graefes Arch Clin Exp Ophthalmol; 2007 Dec; 245(12):1837-42. PubMed ID: 17347807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential effects of bevacizumab, ranibizumab and aflibercept on cell viability, phagocytosis and mitochondrial bioenergetics of retinal pigment epithelial cell.
    Sheu SJ; Chao YM; Liu NC; Chan JY
    Acta Ophthalmol; 2015 Dec; 93(8):e631-43. PubMed ID: 25975662
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the efficacy of aflibercept, ranibizumab, and bevacizumab in an RPE/choroid organ culture.
    Klettner A; Recber M; Roider J
    Graefes Arch Clin Exp Ophthalmol; 2014 Oct; 252(10):1593-8. PubMed ID: 25047874
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exacerbation of choroidal and retinal pigment epithelial atrophy after anti-vascular endothelial growth factor treatment in neovascular age-related macular degeneration.
    Young M; Chui L; Fallah N; Or C; Merkur AB; Kirker AW; Albiani DA; Forooghian F
    Retina; 2014 Jul; 34(7):1308-15. PubMed ID: 24451923
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative toxicity and proliferation testing of aflibercept, bevacizumab and ranibizumab on different ocular cells.
    Schnichels S; Hagemann U; Januschowski K; Hofmann J; Bartz-Schmidt KU; Szurman P; Spitzer MS; Aisenbrey S
    Br J Ophthalmol; 2013 Jul; 97(7):917-23. PubMed ID: 23686000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single- and repeated-dose toxicity study of bevacizumab, ranibizumab, and aflibercept in ARPE-19 cells under normal and oxidative stress conditions.
    Saenz-de-Viteri M; Fernández-Robredo P; Hernández M; Bezunartea J; Reiter N; Recalde S; García-Layana A
    Biochem Pharmacol; 2016 Mar; 103():129-39. PubMed ID: 26793998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.